Skip to main content

Advertisement

Table 1 Baseline characteristics of study groups

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

  BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 P value
Total patient count, n (%) 133 (20 %) 222 (34 %) 166 (25 %) 141 (21 %)  
Age (years), mean (SD) 57.2 (10.4) 58.0 (9.5) 57.3 (9.7) 56.5 (9.8) 0.58*
Gender 0.0495**
 Female, n (%) 62 (46.6) 117 (52.7) 88 (53.0) 89 (63.1)  
 Male, n (%) 71 (53.4) 105 (47.3) 78 (47.0) 52 (36.9)  
Baseline weight (kg), mean (SD) 61.0 (9.0) 73.8 (9.9) 88.9 (11.8) 110.4 (18.6) <0.0001*
Baseline BMI (kg/m2), mean (SD) 23.1 (1.5) 27.6 (1.5) 32.4 (1.4) 40.3 (5.0) <0.0001*
Diabetes duration (years), mean (SD) 13.1 (7.7) 12.4 (6.8) 11.3 (7.1) 10.4 (6.8) 0.0043*
OAD history (years), mean (SD) 5.9 (4.8) 6.4 (6.2) 6.7 (5.4) 5.6 (4.4) 0.29*
Insulin history (years), mean (SD) 2.3 (3.9) 2.2 (3.2) 1.7 (2.5) 1.9 (3.2) 0.35*
  1. BMI body mass index, SD standard deviation, OAD oral antidiabetic drug
  2. * Statistical significance of differences was determined by ANOVA
  3. ** Statistical significance of differences was determined by X2 test